Cargando…

Treatment scheduling effects on the evolution of drug resistance in heterogeneous cancer cell populations

The effect of scheduling of targeted therapy combinations on drug resistance is underexplored in triple-negative breast cancer (TNBC). TNBC constitutes heterogeneous cancer cell populations the composition of which can change dynamically during treatment resulting in the selection of resistant clone...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patwardhan, Gauri A., Marczyk, Michal, Wali, Vikram B., Stern, David F., Pusztai, Lajos, Hatzis, Christos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8154902/ https://www.ncbi.nlm.nih.gov/pubmed/34040000 http://dx.doi.org/10.1038/s41523-021-00270-4

Ejemplares similares

Multi-Omics Investigation of Innate Navitoclax Resistance in Triple-Negative Breast Cancer Cells
por: Marczyk, Michal, et al.
Publicado: (2020)

Identification and Validation of a Novel Biologics Target in Triple Negative Breast Cancer
por: Wali, Vikram B., et al.
Publicado: (2019)

Statistical measures of transcriptional diversity capture genomic heterogeneity of cancer
por: Jiang, Tingting, et al.
Publicado: (2014)

Evaluation of zero counts to better understand the discrepancies between bulk and single-cell RNA-Seq platforms
por: Zyla, Joanna, et al.
Publicado: (2023)

Functional polymorphisms in cancer
por: Agarwal, Divyansh, et al.
Publicado: (2015)

Reliability of Whole-Exome Sequencing for Assessing Intratumor Genetic Heterogeneity
por: Shi, Weiwei, et al.
Publicado: (2018)

Germline variant burden in cancer genes correlates with age at diagnosis and somatic mutation burden
por: Qing, Tao, et al.
Publicado: (2020)

The impact of RNA extraction method on accurate RNA sequencing from formalin-fixed paraffin-embedded tissues
por: Marczyk, Michal, et al.
Publicado: (2019)

Characterization of DNA variants in the human kinome in breast cancer
por: Agarwal, Divyansh, et al.
Publicado: (2015)

Increased epigenetic age in normal breast tissue from luminal breast cancer patients
por: Hofstatter, Erin W., et al.
Publicado: (2018)

Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer
por: Mani, Nikita L., et al.
Publicado: (2016)

Predictors of Chemosensitivity in Triple Negative Breast Cancer: An Integrated Genomic Analysis
por: Jiang, Tingting, et al.
Publicado: (2016)

Functional germline variants as potential co-oncogenes
por: Agarwal, Divyansh, et al.
Publicado: (2017)

Multigene prognostic tests in breast cancer: past, present, future
por: Győrffy, Balázs, et al.
Publicado: (2015)

A genome-wide approach to link genotype to clinical outcome by utilizing next generation sequencing and gene chip data of 6,697 breast cancer patients
por: Pongor, Lőrinc, et al.
Publicado: (2015)

Genomic and Immune Profiling of a Patient With Triple-Negative Breast Cancer That Progressed During Neoadjuvant Chemotherapy Plus PD-L1 Blockade
por: Casadevall, David, et al.
Publicado: (2019)

Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial
por: Li, Xiaotong, et al.
Publicado: (2019)

Targeted RNAseq assay incorporating unique molecular identifiers for improved quantification of gene expression signatures and transcribed mutation fraction in fixed tumor samples
por: Fu, Chunxiao, et al.
Publicado: (2021)

Diverse immune response of DNA damage repair-deficient tumors
por: Qing, Tao, et al.
Publicado: (2021)

An integrative bioinformatics approach reveals coding and non-coding gene variants associated with gene expression profiles and outcome in breast cancer molecular subtypes
por: Győrffy, Balázs, et al.
Publicado: (2018)

Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancers
por: Li, Xiaotong, et al.
Publicado: (2021)

Immunological Differences Between Immune-Rich Estrogen Receptor–Positive and Immune-Rich Triple-Negative Breast Cancers
por: O’Meara, Tess, et al.
Publicado: (2020)

Molecular heterogeneity of breast cancer: implications for treatment and clinical trial design
por: Pusztai, L
Publicado: (2009)

Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
por: Qing, Tao, et al.
Publicado: (2022)

Quantifying Spatial Heterogeneity of Tumor-Infiltrating Lymphocytes to Predict Survival of Individual Cancer Patients
por: Suwalska, Aleksandra, et al.
Publicado: (2022)

Performance of Heterogeneous Algorithm Scheduling in CMSSW
por: Bocci, Andrea, et al.
Publicado: (2023)

The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells
por: Mumenthaler, Shannon M, et al.
Publicado: (2015)

Gene expression profiling of breast cancer
por: Pusztai, Lajos
Publicado: (2009)

Scheduling parallel applications on heterogeneous distributed systems
por: Xie, Guoqi, et al.
Publicado: (2019)

Anti-cancer activities of Schedule E1 drugs used in ayurvedic formulations
por: Vikram, E.N.T., et al.
Publicado: (2022)

Cancer treatment scheduling and dynamic heterogeneity in social dilemmas of tumour acidity and vasculature
por: Kaznatcheev, Artem, et al.
Publicado: (2017)

Mutation based treatment recommendations from next generation sequencing data: a comparison of web tools
por: Patel, Jaymin M., et al.
Publicado: (2016)

Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer
por: Sanft, Tara, et al.
Publicado: (2015)

Evolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance
por: Xue, Yingjiao, et al.
Publicado: (2016)

Tools to use heterogeneous Grid schedulers and storage system
por: Cinquilli, Mattia
Publicado: (2010)

Evaluation of Task Scheduling Algorithms in Heterogeneous Computing Environments
por: Stan, Roxana-Gabriela, et al.
Publicado: (2021)

Predicting prognosis of breast cancer with gene signatures: are we lost in a sea of data?
por: Iwamoto, Takayuki, et al.
Publicado: (2010)

Molecular profiling contributes more than routine histology and immonohistochemistry to breast cancer diagnostics
por: Shiang, Christine, et al.
Publicado: (2010)

Cancer heterogeneity: implications for targeted therapeutics
por: Fisher, R, et al.
Publicado: (2013)

Glucosylceramide synthase upregulates MDR1 expression in the regulation of cancer drug resistance through cSrc and β-catenin signaling
por: Liu, Yong-Yu, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_2adnma578p300jvqa9o0p1lbk5